CXCR4 and neoplasm: Preclinical and early clinical studies suggest that <i>CXCR4</i> blockade can impair tumor growth, limit metastatic spread, and enhance chemotherapy and immunotherapy efficacy, although hematopoietic side effects and infection risk necessitate careful therapeutic design.